Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
Denmark
In shortNordic Bioscience Holding A/s is profitable.
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | – | n/a |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 12.8% | 71/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 36.1% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 0.80× | 0/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | – | n/a |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | – | n/a |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -16.1% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | -1.26× | 0/100 |
| Years with positive free cash flow (last 5) | 2 of 3 | 58/100 |
Weight in the score: 20%
| Profitable years (last 5) | 3 of 3 | 100/100 |
|---|---|---|
| Years of revenue decline (last 5) | 1 of 2 | 17/100 |
| Revenue growth volatility | 138.7% | 0/100 |
| Operating margin volatility | 33.1% | 0/100 |
Weight in the score: 20%
Fiscal year 2025 · change vs prior year
European data comes from annual reports in ESEF format (since 2020). Industry and ticker are not provided by this source.
Annual figures as reported. Hover a bar or point for the exact value.
The last 3 fiscal years from the company's annual reports.
DKK millions; negative values in parentheses.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | 190 | 527 | 426 |
| Cost of revenue | 58 | 62 | – |
| Gross profit | 132 | 457 | 338 |
| Research & development | 112 | 191 | 164 |
| Operating income | (18) | 198 | – |
| Interest expense | – | 4 | 37 |
| Pre-tax income | (21) | 210 | 81 |
| Income tax | (33) | 39 | 26 |
| Net income | 12 | 171 | 55 |
| Diluted EPS | kr0.01 | kr0.16 | kr0.05 |
Not computed: a required balance-sheet item is missing.
3/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: filings.xbrl.org (ESEF). Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Dec 31, 2025 · Data updated Dec 31, 2025